The intestinal microbiota is comprised of the many microorganisms that occupy the gut, performing physiologically important roles in health and disease.  Disruption of the structure and function of the intestinal microbiota is increasingly implicated in a variety of complicated chronic illnesses, including recurrent Clostridium difficile infection, inflammatory bowel disease, obesity, Type 2 diabetes, metabolic syndrome, anxiety, depression and various allergic and autoimmune diseases.  Fecal microbiota transplantation (FMT), the transfer of stool from a healthy individual into a person with a disease presumed to be caused by disrupted microbiota, has emerged as an avant-garde treatment that may improve outcomes of these conditions, for which  treatment options are otherwise limited or incompletely effective.

Our program has leveraged the previous experience and ongoing collaborative research of our teams to create a unique multidisciplinary FMT research program.

Our non-profit program streamlines the provision of FMT by enema or colonoscopy for clinicians and researchers and facilitates long term measurement of multidisciplinary health outcomes beyond those related to the initial FMT indication.

The University of Toronto Microbiota Therapeutics Outcomes Program (MTOP), formerly called the FMT Outcomes (FMTO) Program, is located in Toronto, Canada.  It is a collaborative multidisciplinary program supported by the University of Toronto, the University Health Network, and Sinai Health System.  Patients and study participants receiving FMT are seen at two sites of the University Health Network: the Toronto General Hospital and Toronto Western Hospital. Laboratory donor screening and FMT manufacturing is provided by the University Health Network/Sinai Health System Department of Microbiology located in Mount Sinai Hospital.